Sexual enhancement supplement recalled by manufacturer

February 1, 2007

Ebek, Inc., is conducting a voluntary nationwide recall of its supplement product sold under the name Liviro3. Lab analysis of Liviro3 samples conducted by the FDA found the product contains the phosphodiesterase type-5 inhibitor tadalafil, making Liviro3 an unapproved drug.

Ebek, Inc., is conducting a voluntary nationwide recall of its supplement product sold under the name Liviro3. Lab analysis of Liviro3 samples conducted by the FDA found the product contains the phosphodiesterase type-5 inhibitor tadalafil, making Liviro3 an unapproved drug. The agency described the product as a threat to consumers because tadalafil may interact with nitrates found in some prescription drugs, and may lower blood pressure to dangerous levels.

The FDA advises that tadalafil may cause side effects, such as headaches and flushing.

Liviro3 is sold in 10-tablet boxes or 20-tablet plastic bottles. The product label warns consumers with high blood pressure not to ingest the product, but does not state that it contains tadalafil.

No illnesses have been reported to the company in connection with the product.